Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336594 | 0.92 | DNM1 (0.43) | DNM1TSHRALDH1A1CA12CA1 | |
| SCHEMBL7697421 | 0.89 | DNM1 (0.48) | DNM1TSHRALDH1A1CA12CA1 | |
| SCHEMBL1336606 | 0.81 | FDPS (0.40) | CA1 | |
| SCHEMBL14577078 | 0.76 | MMP1 (0.31) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL18476250 | 0.74 | MMP1 (0.30) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL865548 | 0.73 | MMP1 (0.36) | MMP1MMP2MMP3MMP8DNM1 | |
| SCHEMBL27801853 | 0.73 | CA12 (0.39) | DNM1TSHRLMNAALDH1A1ALDH2 | |
| SCHEMBL10583794 | 0.73 | MMP1 (0.36) | MMP1MMP2MMP3MMP8DNM1 | |
| SCHEMBL11195464 | 0.71 | MMP1 (0.34) | MMP1MMP2MMP3MMP8DNM1 | |
| Hydrochloric Acid SCHEMBL1428262 | 0.71 | DNM1 (0.38) | MMP1MMP2MMP3MMP8DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7307185-B2 | Process for producing optically active fluorochemical | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20070191631-A1 | Process for producing optically active fluorochemical | MITSUBISHI GAS CHEMICAL COMPANY (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1721885-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE FLUOROCHEMICAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191631-A1 | Process for producing optically active fluorochemical | PFAS, CYP4F3, CYP3A43 | MMP1 1364/4885MMP2 1345/4885MMP3 1229/4885 |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | OXA1L, SULT1A1, DAO | MMP1 4728/4885MMP2 4330/4885MMP3 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.